|
Market Cap (17-May) $1,668,273,536 (454th) |
Close (30-Jun) $12.25 |
Volume (30-Jun) 261,029 |
Shortsold (5-May) 7,255,072 (5.76%) (39th) |
|
52w High $24.00 |
52w Low $8.61 |
P/E 76.34 |
EPS 1.09 |
NEU released this announcement to the ASX on 23 December 2022, 9:44. The announcement is marked as price sensitive, and is 3 page(s) in length and 285.67kb in size.
You can view all announcements from NEU and see how they appear on a price chart on the announcements page.
At the date of this announcement, NEU was 0.196% short sold according to ASIC data. It was ranked the 412th most shorted stock on the ASX. It is now ranked as the 39th most shorted stock on the ASX with 5.756% of total shares short sold as of the latest reported data (05 May 2025).
| Other Recent Announcements from NEU | |
|---|---|
| Neuren completes enrolment in Phelan-McDermid Phase 2 trial | 30 June 2023, 9:36 |
| Neuren opens first site in US for Prader-Willi Phase 2 trial | 28 June 2023, 9:55 |
| Change of Director's Interest Notice | 14 June 2023, 18:44 |
| Neuren submits IND & first patients complete Phase 2 trials | 23 December 2022, 9:44 |
| Becoming a substantial holder | 7 December 2022, 10:23 |
| Ceasing to be a substantial holder | 2 December 2022, 7:30 |
| Change in substantial holding | 23 November 2022, 12:12 |
You must be logged in to post a reply.
Neuren Pharmaceuticals 